According to Immunomedics Inc. its experimental lupus drug epratuzumab demonstrated a "clinical meaningful treatment effect" in a study of 227 patients thats purpose was to show which dose is most effective. The company has also said that patients treated with the drug had a 24.9 percent improvement in symptoms than if treated with placebo. After failing an earlier midstage study many analysts have been surprised by epratuzumab"s success. The drug"s function is not clearly understood but it appears to interrupt the supply of antibodies that cause lupus and other autoimmune diseases by reducing the activity of B-cells.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지